Search

Your search keyword '"Fallowfield, L."' showing total 891 results
Start Over Author "Fallowfield, L."
891 results on '"Fallowfield, L."'

3. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Author

Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M.-J., Carey, L.A., Cortés, J., El Saghir, N.S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S.-B., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., and Winer, E.P.

Published
2020
Full Text
View/download PDF

4. The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial

Author

Leonard R, Yellowlees A, Mansi J, Fallowfield L, and Jenkins V

Subjects
OPTION trial, Pre-menopausal, Breast cancer, Goserelin, Chemotherapy, Quality of life, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: The OPTION trial results showed that premenopausal women with early stage breast cancer (EBC) receiving chemotherapy benefited from ovarian function protection with goserelin. The impact of treatments on patient reported Quality of Life (QoL) were also examined. Patients and methods: 227 pre-menopausal women with EBC, were randomly assigned to chemotherapy±goserelin (C±G); 132 (58%) were ER-ve. Patients were stratified by age (≤40 years and >40 years). QoL was assessed with the Functional Assessment of Cancer Therapy – Breast, and Endocrine Symptom checklist at baseline (pre-treatment), 3, 6, 12, 18 and 24 months, then annually to 5 years. Treatment Outcome Index (TOI) score was the primary outcome. Results: 213 patients were available for QoL analysis. There was a significant decrease in TOI scores for both treatment groups at 3 and 6 months that returned to pre-treatment levels at 12 months, then continued to increase reflecting improved QoL. By 3 months there was a significant difference from baseline in both groups for menopausal symptoms, and between groups in the proportion experiencing hot flushes at any time. The C + G group experienced higher levels of vasomotor symptoms generally during the treatment phase; by 24 months, the short-term negative effect of goserelin was reversed, with hot flushes twice as frequent in the chemotherapy only group (40.9% vs 21.3%). Conclusions: These results show that young women diagnosed with breast cancer experienced only a short-term decrease in QoL from the addition of goserelin, in order to preserve ovarian function during chemotherapy treatment.

Published
2020
Full Text
View/download PDF

6. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Author

Delaloge, S., Cella, D., Ye, Y., Buyse, M., Chan, A., Barrios, C.H., Holmes, F.A., Mansi, J., Iwata, H., Ejlertsen, B., Moy, B., Chia, S.K.L., Gnant, M., Smichkoska, S., Ciceniene, A., Martinez, N., Filipović, S., Ben-Baruch, N.E., Joy, A.A., Langkjer, S.T., Senecal, F., de Boer, R.H., Moran, S., Yao, B., Bryce, R., Auerbach, A., Fallowfield, L., and Martin, M.

Published
2019
Full Text
View/download PDF

8. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Author

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C.H., Bergh, J., Biganzoli, L., Boers-Doets, C.B., Cardoso, M.J., Carey, L.A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N.S., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Johnston, S.R.D., Kaufman, B., Koppikar, S., Krop, I.E., Mayer, M., Nakigudde, G., Offersen, B.V., Ohno, S., Pagani, O., Paluch-Shimon, S., Penault-Llorca, F., Prat, A., Rugo, H.S., Sledge, G.W., Spence, D., Thomssen, C., Vorobiof, D.A., Xu, B., Norton, L., and Winer, E.P.

Published
2018
Full Text
View/download PDF

11. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

Author

Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., and Winer, E.

Published
2017
Full Text
View/download PDF

13. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Author

Vrdoljak, E., Marschner, N., Zielinski, C., Gligorov, J., Cortes, J., Puglisi, F., Aapro, M., Fallowfield, L., Fontana, A., Inbar, M., Kahan, Z., Welt, A., Lévy, C., Brain, E., Pivot, X., Putzu, C., González Martín, A., de Ducla, S., Easton, V., and von Minckwitz, G.

Published
2016
Full Text
View/download PDF

15. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Author

Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Biganzoli, L., Blackwell, K.L., Cardoso, M.J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S.H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U.N., Mayer, M., Merjaver, S.D., Nordström, E.B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M.J., Rugo, H., Sledge, G., Thomssen, C., van’t Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., and Winer, E.

Published
2014
Full Text
View/download PDF

16. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Author

Fallowfield, Lesley, Jenkins, Valerie, Kilkerr, Justine, Langridge, Carolyn, Monson, Kathryn, Jakobsen, Erik Hugger, Nielsen, Mette Holck, Linnet, Soeren, Knoop, Ann, Pivot, Xavier, Bonnefoi, Herve, Mousseau, Mireille, Zelek, Laurent, Bourgeois, Hugues, Lefeuvre, Claudia Plesse, Bachelot, Thomas, Petit, Thierry, Brain, Etienne, Levy, Christelle, Gligorov, Joseph, Augustin, Doris, Graf, Heiko, Heinrich, Georg, Kroening, Hendrik, Kuemmel, Sherko, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-Won, Schmidt, Marcus, Perlova-Griff, Lidia, Wolf, Christopher, Colleoni, Marco, Ballestrero, Alberto, Bernardo, Antonio, Ribecco, Angela Stefania, Gianni, Luca, Curigliano, Giuseppe, Brewczynska, Elżbieta, Jassem, Jacek, Shirinkin, Vadim, Manikhas, Alexey, Dvornichenko, Victoria, Lichinitser, Mikhail, Semiglazov, Vladimir, Mukhametshina, Guzel, Bulavina, Irina, Arranz, Enrique Espinosa, Ocon, Francisco Carabantes, Vivanco, Guillermo López, Bofill, Javier Salvador, Quintela, Ignacio Porras, Muñoz, Alfonso Sanchez, Pérez, Yolanda Fernández, Espinosa, Javier Cassinello, Alvarez, José Valero, del Prado, Rodrigo Lastra, De Merino, LuisLa Cruz, García, José Manuel Pérez, Frances, Santos Enrech, Edlund, Per, Norberg, Bengt, Wennstig, Anna-Karin, Lind, Pehr, Hauser, Nik, Tausch, Christoph, Camci, Celalettin, Arpaci, Fikret, Abali, Huseyin, Uslu, Ruchan, Tahir, Saad, Wheatley, Duncan, Chan, Stephen, Barrett-Lee, Peter, McAdam, Karen, Simcock, Richard, Burcombe, Russell, El-Maraghi, Robert, Califaretti, Nadia, Spadafora, Silvana, Sehdev, Sandeep, Sami, Amer, Verma, Sunil, Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., and Fallowfield, L.

Published
2014
Full Text
View/download PDF

20. A digital pathway for genetic testing in UK NHS cancer patients: BRCA-DIRECT randomised study internal pilot

Author

Torr, B, Jones, C, Choi, S, Allen, S, Kavanaugh, G, Garrett, A, MacMahon, S, Loong, L, Reay, A, Yuan, L, Valganon Petrizan, M, Monson, K, Perry, N, Fallowfield, L, Jenkins, V, Gold, R, Taylor, A, Gabe, R, Wiggins, J, Lucassen, A, Manchanda, R, Gandhi, A, George, A, Hubank, M, Kemp, Z, Evans, DG, Bremner, S, and Turnbull, C

Abstract

Background\ud Germline genetic testing affords multiple opportunities for women with breast cancer, however, current UK NHS models for delivery of germline genetic testing are clinician-intensive and only a minority of breast cancer cases access testing.\ud \ud Methods\ud We designed a rapid, digital pathway, supported by a genetics specialist hotline, for delivery of germline testing of BRCA1/BRCA2/PALB2 (BRCA-testing), integrated into routine UK NHS breast cancer care. We piloted the pathway, as part of the larger BRCA-DIRECT study, in 130 unselected breast cancer patients and gathered preliminary data from a randomised comparison of delivery of pre-test information digitally (fully-digital pathway) or via telephone consultation with a genetics professional (partially-digital pathway).\ud \ud Results\ud Uptake of genetic testing was 98.4%, with good satisfaction reported for both the fully- and partially-digital pathways. Similar outcomes were observed in both arms regarding patient knowledge score and anxiety, with

Published
2022

21. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Author

Cardoso, F, Costa, A, Senkus, E, Aapro, M, André, F, Barrios, C H, Bergh, J, Bhattacharyya, G, Biganzoli, L, Cardoso, M J, Carey, L, Corneliussen-James, D, Curigliano, G, Dieras, V, El Saghir, N, Eniu, A, Fallowfield, L, Fenech, D, Francis, P, Gelmon, K, Gennari, A, Harbeck, N, Hudis, C, Kaufman, B, Krop, I, Mayer, M, Meijer, H, Mertz, S, Ohno, S, Pagani, O, Papadopoulos, E, Peccatori, F, Penault-Llorca, F, Piccart, M J, Pierga, J Y, Rugo, H, Shockney, L, Sledge, G, Swain, S, Thomssen, C, Tutt, A, Vorobiof, D, Xu, B, Norton, L, and Winer, E

Published
2017
Full Text
View/download PDF

23. 1st International consensus guidelines for advanced breast cancer (ABC 1)

Author

Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., Pagani, O., Senkus, E., Thomssen, C., Aapro, M., Bergh, J., Di Leo, A., El Saghir, N., Ganz, P.A., Gelmon, K., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Leadbeater, M., Mayer, M., Rodger, A., Rugo, H., Sacchini, V., Sledge, G., van’t Veer, L., Viale, G., Krop, I., and Winer, E.

Published
2012
Full Text
View/download PDF

29. POSNOC—POsitive Sentinel NOde : adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy : a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes

Author

Goyal, A., Mann, G.B., Fallowfield, L., Duley, L., Reed, M., Dodwell, D., Coleman, R.E., Fakis, A., Newcombe, R., Jenkins, V., Whitham, D., Childs, M., Whynes, D., Keeley, V., Ellis, I., Fairbrother, P., Sadiq, S., Monson, K., Montgomery, A., Tan, W., Vale, L., Homer, T., Badger, H., Haines, R.H., Lewis, M., Megias, D., Nabi, Z., Singh, P., Caraman, A., Miles, E., and POSNOC Trialists, (on behalf of)

Abstract

Introduction: ACOSOG-Z0011(Z11) trial showed that axillary node clearance (ANC) may be omitted in women with ≤2 positive nodes undergoing breast conserving surgery (BCS) and whole breast radiotherapy (RT). A confirmatory study is needed to clarify the role of axillary treatment in women with ≤2 macrometastases undergoing BCS and groups that were not included in Z11 for example, mastectomy and those with microscopic extranodal invasion. The primary objective of POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy (POSNOC) is to evaluate whether for women with breast cancer and 1 or 2 macrometastases, adjuvant therapy alone is non-inferior to adjuvant therapy plus axillary treatment, in terms of 5-year axillary recurrence.\ud \ud \ud \ud Methods and analysis: POSNOC is a pragmatic, multicentre, non-inferiority, international trial with participants randomised in a 1:1 ratio. Women are eligible if they have T1/T2, unifocal or multifocal invasive breast cancer, and 1 or 2 macrometastases at sentinel node biopsy, with or without extranodal extension. In the intervention group women receive adjuvant therapy alone, in the standard care group they receive ANC or axillary RT. In both groups women receive adjuvant therapy, according to local guidelines. This includes systemic therapy and, if indicated, RT to breast or chest wall. The UK Radiotherapy Trials Quality Assurance Group manages the in-built radiotherapy quality assurance programme. Primary endpoint is 5-year axillary recurrence. Secondary outcomes are arm morbidity assessed by Lymphoedema and Breast Cancer Questionnaire and QuickDASH questionnaires; quality of life and anxiety as assessed with FACT B+4 and State/Trait Anxiety Inventory questionnaires, respectively; other oncological outcomes; economic evaluation using EQ-5D-5L. Target sample size is 1900. Primary analysis is per protocol. Recruitment started on 1 August 2014 and as of 9 June 2021, 1866 participants have been randomised.\ud \ud \ud \ud Ethics and dissemination: Protocol was approved by the National Research Ethics Service Committee East Midlands—Nottingham 2 (REC reference: 13/EM/0459). Results will be submitted for publication in peer-reviewed journals.\ud \ud \ud \ud Trial registration number: ISRCTN54765244; NCT0240168Cite Now

Published
2021

30. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

Author

Palmieri, C., Cleator, S., Kilburn, L. S., Kim, S. B., Ahn, S.-H., Beresford, M., Gong, G., Mansi, J., Mallon, E., Reed, S., Mousa, K., Fallowfield, L., Cheang, M., Morden, J., Page, K., Guttery, D. S., Rghebi, B., Primrose, L., Shaw, J. A., Thompson, A. M., Bliss, J. M., and Coombes, R. C.

Published
2014
Full Text
View/download PDF

34. Summary

Author

Coates, A., Fallowfield, L., Schlag, P. M., editor, Senn, H.-J., editor, Diehl, V., editor, Parkin, D. M., editor, Rajewsky, M. F., editor, Rubens, R., editor, Wannenmacher, M., editor, Senn, Hans-Jörg, editor, Gelber, Richard D., editor, Goldhirsch, Aron, editor, and Thürlimann, Beat, editor

Published
1998
Full Text
View/download PDF

36. Patientsʼ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Author

Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., Fallowfield, Lesley, Jenkins, Valerie, Kilkerr, Justine, Langridge, Carolyn, Monson, Kathryn, Jakobsen, Erik Hugger, Nielsen, Mette Holck, Linnet, Soeren, Knoop, Ann, Pivot, Xavier, Bonnefoi, Herve, Mousseau, Mireille, Zelek, Laurent, Bourgeois, Hugues, Lefeuvre, Claudia Plesse, Bachelot, Thomas, Petit, Thierry, Brain, Etienne, Levy, Christelle, Gligorov, Joseph, Augustin, Doris, Graf, Heiko, Heinrich, Georg, Kroening, Hendrik, Kuemmel, Sherko, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-Won, Schmidt, Marcus, Perlova-Griff, Lidia, Wolf, Christopher, Colleoni, Marco, Ballestrero, Alberto, Bernardo, Antonio, Ribecco, Angela Stefania, Gianni, Luca, Curigliano, Giuseppe, Brewczynska, Elżbieta, Jassem, Jacek, Shirinkin, Vadim, Manikhas, Alexey, Dvornichenko, Victoria, Lichinitser, Mikhail, Semiglazov, Vladimir, Mukhametshina, Guzel, Bulavina, Irina, Arranz, Enrique Espinosa, Ocon, Francisco Carabantes, Vivanco, Guillermo López, Bofill, Javier Salvador, Quintela, Ignacio Porras, Muñoz, Alfonso Sanchez, Pérez, Yolanda Fernández, Espinosa, Javier Cassinello, Alvarez, José Valero, del Prado, Rodrigo Lastra, Merino, Luis De La Cruz, García, José Manuel Pérez, Frances, Santos Enrech, Edlund, Per, Norberg, Bengt, Wennstig, Anna-Karin, Lind, Pehr, Hauser, Nik, Tausch, Christoph, Camci, Celalettin, Arpaci, Fikret, Abali, Huseyin, Uslu, Ruchan, Tahir, Saad, Wheatley, Duncan, Chan, Stephen, Barrett-Lee, Peter, McAdam, Karen, Simcock, Richard, Burcombe, Russell, El-Maraghi, Robert, Califaretti, Nadia, Spadafora, Silvana, Sehdev, Sandeep, Sami, Amer, and Verma, Sunil

Published
2014
Full Text
View/download PDF

40. POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes

Author

Goyal, A, Mann, GB, Fallowfield, L, Duley, L, Reed, M, Dodwell, D, Coleman, RE, Fakis, A, Newcombe, R, Jenkins, V, Whitham, D, Childs, M, Whynes, D, Keeley, V, Ellis, I, Fairbrother, P, Sadiq, S, Monson, K, Montgomery, A, Tan, W, Vale, L, Homer, T, Badger, H, Haines, RH, Lewis, M, Megias, D, Nabi, Z, Singh, P, Caraman, A, Miles, E, Goyal, A, Mann, GB, Fallowfield, L, Duley, L, Reed, M, Dodwell, D, Coleman, RE, Fakis, A, Newcombe, R, Jenkins, V, Whitham, D, Childs, M, Whynes, D, Keeley, V, Ellis, I, Fairbrother, P, Sadiq, S, Monson, K, Montgomery, A, Tan, W, Vale, L, Homer, T, Badger, H, Haines, RH, Lewis, M, Megias, D, Nabi, Z, Singh, P, Caraman, A, and Miles, E

Abstract

INTRODUCTION: ACOSOG-Z0011(Z11) trial showed that axillary node clearance (ANC) may be omitted in women with ≤2 positive nodes undergoing breast conserving surgery (BCS) and whole breast radiotherapy (RT). A confirmatory study is needed to clarify the role of axillary treatment in women with ≤2 macrometastases undergoing BCS and groups that were not included in Z11 for example, mastectomy and those with microscopic extranodal invasion. The primary objective of POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy (POSNOC) is to evaluate whether for women with breast cancer and 1 or 2 macrometastases, adjuvant therapy alone is non-inferior to adjuvant therapy plus axillary treatment, in terms of 5-year axillary recurrence. METHODS AND ANALYSIS: POSNOC is a pragmatic, multicentre, non-inferiority, international trial with participants randomised in a 1:1 ratio. Women are eligible if they have T1/T2, unifocal or multifocal invasive breast cancer, and 1 or 2 macrometastases at sentinel node biopsy, with or without extranodal extension. In the intervention group women receive adjuvant therapy alone, in the standard care group they receive ANC or axillary RT. In both groups women receive adjuvant therapy, according to local guidelines. This includes systemic therapy and, if indicated, RT to breast or chest wall. The UK Radiotherapy Trials Quality Assurance Group manages the in-built radiotherapy quality assurance programme. Primary endpoint is 5-year axillary recurrence. Secondary outcomes are arm morbidity assessed by Lymphoedema and Breast Cancer Questionnaire and QuickDASH questionnaires; quality of life and anxiety as assessed with FACT B+4 and State/Trait Anxiety Inventory questionnaires, respectively; other oncological outcomes; economic evaluation using EQ-5D-5L. Target sample size is 1900. Primary analysis is per protocol. Recruitment started on 1 August 2014 and as of 9 June 2021, 1866 participants have bee

Published
2021

47. 165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study

Author

O'Shaughnessy, J., primary, Sousa, S., additional, Cruz, J., additional, Fallowfield, L., additional, Auvinen, P., additional, Pulido, C., additional, Cvetanovic, A., additional, Wilks, S., additional, Ribeiro, L., additional, Burotto, M., additional, Klingbiel, D., additional, Messeri, D., additional, Alexandrou, A., additional, Trask, P., additional, Fredriksson, J., additional, Machackova, Z., additional, and Stamatovic, L., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results